| Literature DB >> 27408923 |
Eline Desmet1, Stefanie Bracke1, Katrien Forier2, Lien Taevernier3, Marc C A Stuart4, Bart De Spiegeleer3, Koen Raemdonck5, Mireille Van Gele1, Jo Lambert1.
Abstract
This article contains original data, figures and methods used in the characterization of the liposomal carrier 'DDC642' for topical applications, described in "An elastic liposomal formulation for RNAi-based topical treatment of skin disorders: proof-of-concept in the treatment of psoriasis" (Desmet et al., 2016) [1]. Several elastic liposomal formulations have been evaluated for their ability to encapsulate and deliver RNA interference (RNAi) molecules to cultured primary skin cells. The efficiency and effectiveness of these liposomes were compared to that of our previously characterized liposomes, the 'SECosomes' (SEC) (Geusens et al., 2010) [2]. After selection of a potential superior carrier, based on encapsulation and transfection efficiency data (Desmet et al., 2016) [1], the selected DDC642 liposomes were characterized more in-depth. Herein, a detailed characterization of the DDC642 liposome and RNAi-loaded lipoplexes is given, including the matching protocols.Entities:
Keywords: Gene therapy; Lipid-based nanoparticle; Liposome; RNA interference; Topical drug delivery
Year: 2016 PMID: 27408923 PMCID: PMC4927961 DOI: 10.1016/j.dib.2016.03.091
Source DB: PubMed Journal: Data Brief ISSN: 2352-3409
Fig. 1Images of the gel retardation assays using siRNA- and miRNA-containing complexes. For information about the composition and physicochemical parameters of the liposomes and corresponding lipoplexes see Table A in Ref. [1].
Fig. 2Cryo-TEM images of DDC642 liposomes (A) and lipoplexes (B). Scale bar:100 nm.
Transfection efficiency of the liposomes in cultured primary skin cells. The percentages of transfected cells were analyzed 4 h post-treatment with a final concentration of 25 nm small RNA molecules (⁎) or 24 h with 50 nm (†). Grey colored: transfection conditions as described in Ref. [1] and Fig. 4C.
| % transfected cells | siRNA⁎ | |||
|---|---|---|---|---|
| HiPerfect | 99.9 | 49.3 | 5.0 | |
| SEC | 99.9 | 41.7 | 40.8 | |
| DDC642 | 99.9 | 46.8 | 12.0 | |
| HiPerfect | 99.9 | 20.7 | 37.2 | 29.2 |
| SEC | 99.9 | 16.6 | 63.0 | 94.2 |
| DDC642 | 99.9 | 69.1 | 73.2 | 96.0 |
| HiPerfect | 99.9 | 30.9 | 8.14 | |
| SEC | 99.9 | 49.3 | 61.3 | |
| DDC642 | 99.9 | 46.6 | 25.5 |
Fig. 3MyoVa protein expression after pre-miR-145 transfection of melanocytes. (A) Representative blot of untreated and treated cells. Lane 1: untreated; lane 2 and 5: empty vehicle; lane 3 and 6: pre-miR negative control #2; lane 4 and 7: pre-miR-145. (B) Quantitative analysis of the gels. Samples were compared to untreated control and α-tubulin was used as loading control. Error bars represent the mean±SD (n=3). P-values<0.05* compared to untreated control, † compared to HiPerfect.
Fig. 4Cytotoxicity and stability assessment. (A) Cell viability of melanocytes (MC) and keratinocytes (KC) with increasing amounts of liposomes for 4 h. (B, C) Physicochemical and biological activity of lipoplexes during storage. The expression level of hBD-2 is relative to that of cells transfected with scrambled siRNA (100%). Data is shown as mean±SD (n≥3). P-values<0.05* compared to 5 µg mL−1 (A) or day 0 condition (B, C).
| Subject area | |
|---|---|
| More specific subject area | |
| Type of data | |
| How data were acquired | |
| Data format | |
| Experimental factors | |
| Experimental features | |
| Data source location | |
| Data accessibility |